var data={"title":"Seborrheic dermatitis in adolescents and adults","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Seborrheic dermatitis in adolescents and adults</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/contributors\" class=\"contributor contributor_credentials\">Denis Sasseville, MD, FRCPC</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/contributors\" class=\"contributor contributor_credentials\">Joseph Fowler, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 12, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H34051752\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Seborrheic dermatitis is a chronic, relapsing, and usually mild form of dermatitis that occurs in infants and in adults. The severity may vary from minimal, asymptomatic scaliness of the scalp (dandruff) to more widespread involvement. Affected individuals are usually healthy, although seborrheic dermatitis has been associated with human immunodeficiency virus (HIV) infection, Parkinson disease, a number of other neurologic disorders, and use of neuroleptic medications.</p><p>This topic will discuss the pathogenesis, clinical manifestations, and management of seborrheic dermatitis in adolescents and adults. The infantile form of seborrheic dermatitis is discussed separately. (See <a href=\"topic.htm?path=cradle-cap-and-seborrheic-dermatitis-in-infants\" class=\"medical medical_review\">&quot;Cradle cap and seborrheic dermatitis in infants&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H34051759\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Seborrheic dermatitis has a biphasic incidence, occurring in infants between the ages of 2 weeks and 12 months and, later, during adolescence and adulthood. The prevalence of clinically significant seborrheic dermatitis is approximately 3 percent, with peak prevalence in the third and fourth decades [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/1\" class=\"abstract_t\">1</a>]. The actual prevalence is probably much higher when mild cases are included. Men are affected more frequently than women.</p><p>The prevalence of seborrheic dermatitis is increased among individuals with human immunodeficiency virus (HIV) infection, in whom it may be a presenting sign. The prevalence has been estimated to be around 35 percent among patients with early HIV infection and up to 85 percent among patients with acquired immunodeficiency syndrome (AIDS) [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/2,3\" class=\"abstract_t\">2,3</a>].</p><p>Patients with parkinsonism frequently present with seborrhea (oily skin) and seborrheic dermatitis, both of which may improve with L-dopa therapy [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/4,5\" class=\"abstract_t\">4,5</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-of-parkinson-disease#H9\" class=\"medical medical_review\">&quot;Clinical manifestations of Parkinson disease&quot;, section on 'Nonmotor symptoms'</a>.)</p><p class=\"headingAnchor\" id=\"H34051766\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The cause of seborrheic dermatitis is not known. Seborrheic dermatitis is not a disease of the sebaceous glands nor is the rate of sebum excretion increased in patients with seborrheic dermatitis [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/6\" class=\"abstract_t\">6</a>]. Nonetheless, sebaceous glands appear to be necessary for the development of seborrheic dermatitis as indicated by the predilection for body sites with increased numbers of sebaceous glands and larger sebaceous glands (face, scalp, upper trunk, external auditory meatus, and anogenital area). In addition, the infantile form is common early in the first year of life, when androgen-producing, enlarged, neonatal adrenal glands and transplacental transfer of maternal androgens stimulate the growth of the infant's sebaceous glands.</p><p>Sebaceous glands may play a permissive role in the pathogenesis of seborrheic dermatitis, possibly by creating a favorable milieu for the growth of fungi of the genus <em>Malassezia</em>. The lipid-dependent <em>Malassezia</em> (formerly known as <em>Pityrosporum ovale</em>) is a saprophyte of normal skin that thrives at the sites of predilection for seborrheic dermatitis [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/7,8\" class=\"abstract_t\">7,8</a>]. The use of molecular markers, such as 26S rDNA, ITS, and 5.8S, has allowed better species identification and revealed intraspecies differences that could be related to pathogenicity [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/9,10\" class=\"abstract_t\">9,10</a>]. However, there is limited direct evidence that <em>Malassezia</em> is implicated in the etiology of seborrheic dermatitis. Studies have failed to demonstrate a higher density of <em>Malassezia</em> on the skin of affected individuals or a relationship between the intensity of skin colonization and severity of seborrheic dermatitis, although some specific <em>Malassezia</em> species have been detected more frequently on affected skin than on normal skin [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/11-13\" class=\"abstract_t\">11-13</a>]. A higher density of <em>Malassezia</em> has been demonstrated in patients with Parkinson disease and seborrheic dermatitis compared with controls, with a predominance of <em>Malassezia globosa</em> displaying high production of lipases and phosphatases [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/14\" class=\"abstract_t\">14</a>].</p><p>Indirect evidence for a role of <em>Malassezia</em> in seborrheic dermatitis derives from the observation that most of the effective therapeutic agents have antifungal activity. However, the nonspecific anti-inflammatory effect of the azole antifungal agents commonly used for seborrheic dermatitis may also explain their efficacy, given that some studies have been unable to demonstrate in vivo a decrease in <em>Malassezia</em> colonization after treatment with topical <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/15\" class=\"abstract_t\">15</a>].</p><p>Observational studies suggest that in some patients seborrheic dermatitis may result from the host's immune response to <em>Malassezia</em> or to its byproducts (eg, lipases or free fatty acids) [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/16,17\" class=\"abstract_t\">16,17</a>]. Other studies, however, were unable to find humoral or cellular immunologic abnormalities in patients with seborrheic dermatitis [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/18\" class=\"abstract_t\">18</a>]. The inflammation of seborrheic dermatitis may be irritant-mediated rather than immune-mediated, due to <em>Malassezia</em> production of free fatty acids, lipase, and reactive oxygen species [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/16\" class=\"abstract_t\">16</a>]. The lipases and phospholipases produced by <em>Malassezia</em> cleave free fatty acids from triglycerides present in sebum, which are known irritants and can induce inflammation. In addition, lipases and phosphatases damage surrounding cells with release of oleic and arachidonic acid from their walls. Arachidonic acid is further metabolized by cyclooxygenase in proinflammatory eicosanoids [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/14\" class=\"abstract_t\">14</a>]. Additional factors that may be playing a role in the inflammation of seborrheic dermatitis include oxidative stress and the overproduction of cell-damaging oxygen radicals [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/19\" class=\"abstract_t\">19</a>].</p><p>The reason for the increased susceptibility of patients with human immunodeficiency virus (HIV) infection to seborrheic dermatitis is not known. A transgenic mouse deficient in CD4+ and CD8+ cells has been shown to develop a seborrheic dermatitis-like skin disease, an overgrowth of yeast cells in hair follicles, and an improvement with <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/19\" class=\"abstract_t\">19</a>]. This suggests that dysregulation of the immune system may play a role in the increased prevalence of seborrheic dermatitis in the immunocompromised host. The relationship between seborrheic dermatitis and neurologic disorders is also poorly understood. Patients with Parkinson disease often have increased sebum production; in these patients, seborrhea and seborrheic dermatitis improve with L-dopa therapy [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/4,5\" class=\"abstract_t\">4,5</a>].</p><p class=\"headingAnchor\" id=\"H34051773\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Seborrheic dermatitis may first appear soon after puberty or later in life. It is usually characterized by well-demarcated, erythematous plaques with greasy-looking, yellowish scales distributed on areas rich in sebaceous glands, such as the scalp, the external ear, the center of the face, the upper part of the trunk, and the intertriginous areas (<a href=\"image.htm?imageKey=DERM%2F56410%7EDERM%2F82073%7EDERM%2F59104\" class=\"graphic graphic_picture graphicRef56410 graphicRef82073 graphicRef59104 \">picture 1A-C</a>).</p><p class=\"headingAnchor\" id=\"H498821253\"><span class=\"h2\">Scalp</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The mildest and most common form of scalp seborrheic dermatitis is dandruff, also known as pityriasis sicca, in which the scalp shows fine, white, diffuse scaliness without underlying erythema (<a href=\"image.htm?imageKey=DERM%2F54173\" class=\"graphic graphic_picture graphicRef54173 \">picture 2</a>). Dandruff may be asymptomatic or accompanied by mild pruritus. More severe forms of scalp seborrheic dermatitis present with visible inflammation, consisting of patchy, orange to salmon-colored or grayish plaques covered with yellowish, greasy scales (pityriasis steatoides), mostly over the temporoparietal areas (<a href=\"image.htm?imageKey=DERM%2F76985%7EDERM%2F114660\" class=\"graphic graphic_picture graphicRef76985 graphicRef114660 \">picture 3A-B</a>) or with concretions of scale around hair shafts (pityriasis amiantacea) (<a href=\"image.htm?imageKey=DERM%2F114661\" class=\"graphic graphic_picture graphicRef114661 \">picture 3C</a>). Lesions may extend to the postauricular areas (<a href=\"image.htm?imageKey=DERM%2F82073\" class=\"graphic graphic_picture graphicRef82073 \">picture 1B</a>), where they often develop fissures, oozing, and crusting, and to the outer canal and concha of the ear, sometimes with marked pruritus and superinfection (otitis externa). (See <a href=\"topic.htm?path=external-otitis-pathogenesis-clinical-features-and-diagnosis#H3\" class=\"medical medical_review\">&quot;External otitis: Pathogenesis, clinical features, and diagnosis&quot;, section on 'Pathogenesis and risk factors'</a>.)</p><p class=\"headingAnchor\" id=\"H498821260\"><span class=\"h2\">Face</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Facial lesions favor the forehead below the hairline, the eyebrows and glabella (<a href=\"image.htm?imageKey=DERM%2F114660\" class=\"graphic graphic_picture graphicRef114660 \">picture 3B</a>), and the nasolabial folds. They may extend to the cheeks and malar areas in a butterfly distribution (<a href=\"image.htm?imageKey=DERM%2F114634%7EDERM%2F65167%7EDERM%2F59104\" class=\"graphic graphic_picture graphicRef114634 graphicRef65167 graphicRef59104 \">picture 1C-E</a>). The mustache and beard area are frequently involved in men with facial hair. Shaving helps with treatment and control of the disease.</p><p class=\"headingAnchor\" id=\"H498821267\"><span class=\"h2\">Periocular</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Blepharitis with redness of the free margin of the eyelids and yellow crusting between the eyelashes may be the sole manifestation of seborrheic dermatitis or may accompany its more classic distribution. (See <a href=\"topic.htm?path=blepharitis#H8\" class=\"medical medical_review\">&quot;Blepharitis&quot;, section on 'Clinical findings'</a>.)</p><p class=\"headingAnchor\" id=\"H498821274\"><span class=\"h2\">Trunk</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Five patterns of truncal involvement have been described:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Moist, erythematous intertrigo of the axillae, inframammary folds, umbilicus, and genitocrural area (<a href=\"image.htm?imageKey=DERM%2F53407\" class=\"graphic graphic_picture graphicRef53407 \">picture 1F</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The &quot;petaloid pattern,&quot; consisting of polycyclic, finely scaly, thin plaques over the sternum or interscapular area</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Annular or arcuate, round to oval, slightly scaly plaques on the trunk, sometimes with hypopigmented central clearing, known as &quot;seborrheic eczematids&quot;</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The pityriasiform pattern mimicking pityriasis rosea, comprised of 5 to 15 mm, oval-shaped, scaly lesions distributed along the skin tension lines</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The psoriasiform pattern with larger red, rounded plaques, covered with thicker scales</p><p/><p class=\"headingAnchor\" id=\"H498821343\"><span class=\"h2\">In patients with human immunodeficiency virus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Seborrheic dermatitis tends to be more extensive and severe in human immunodeficiency <span class=\"nowrap\">virus/acquired</span> immunodeficiency syndrome <span class=\"nowrap\">(HIV/AIDS)</span> patients. It sometimes involves unusual sites, such as the extremities, and may be difficult to control [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/3,20\" class=\"abstract_t\">3,20</a>]. Seborrheic dermatitis is frequently observed in patients with CD4 counts &lt;400 <span class=\"nowrap\">cells/microL</span> and is more diffuse and severe in patients with CD4 counts &lt;200 <span class=\"nowrap\">cells/microL</span> [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/21,22\" class=\"abstract_t\">21,22</a>]. It may regress with antiretroviral therapy (ART). However, seborrheic dermatitis also may be a cutaneous manifestation of the immune reconstitution inflammatory syndrome in patients on ART [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/23\" class=\"abstract_t\">23</a>]. (See <a href=\"topic.htm?path=immune-reconstitution-inflammatory-syndrome#H18\" class=\"medical medical_review\">&quot;Immune reconstitution inflammatory syndrome&quot;, section on 'Miscellaneous syndromes possibly associated with IRIS'</a>.)</p><p class=\"headingAnchor\" id=\"H498821317\"><span class=\"h1\">CLINICAL COURSE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Seborrheic dermatitis is a chronic, relapsing condition that may go on for decades. It tends to worsen with stress and during the cold and dry winter months. It tends to improve during the summer months, probably from sun exposure, although it may be precipitated by psoralen plus ultraviolet A (PUVA) therapy [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/24\" class=\"abstract_t\">24</a>]. The available treatments do not cure seborrheic dermatitis and must be repeated or continued intermittently to prevent recurrence. (See <a href=\"#H27253022\" class=\"local\">'Management'</a> below.)</p><p class=\"headingAnchor\" id=\"H710057309\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of seborrheic dermatitis is usually made clinically based on the appearance and location of the lesions. (See <a href=\"#H34051773\" class=\"local\">'Clinical manifestations'</a> above.)</p><p>Biopsy is not routinely necessary but may be indicated when the diagnosis is uncertain. (See <a href=\"#H34051795\" class=\"local\">'Differential diagnosis'</a> below.)</p><p class=\"headingAnchor\" id=\"H34051788\"><span class=\"h2\">Histopathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no uniquely characteristic or pathognomonic histologic features in seborrheic dermatitis. In human immunodeficiency virus (HIV)-negative patients, histology shows focal parakeratosis in the horny layer of the epidermis; mounds of scale-crusts with pyknotic neutrophils on the lips of dilated, sometimes plugged, follicular ostia; psoriasiform acanthosis; and mild to moderate spongiosis. The dermis harbors a sparse, perivascular, lymphohistiocytic inflammatory infiltrate. In chronic cases, the histologic picture may be difficult to distinguish from psoriasis, but the presence of even a minimal degree of spongiosis should favor a diagnosis of seborrheic dermatitis.</p><p>In <span class=\"nowrap\">HIV/acquired</span> immunodeficiency syndrome (AIDS) patients, the histopathologic changes parallel the severity of the disease. Parakeratosis is more widespread, and the epidermis shows necrotic keratinocytes. Spongiosis is less prominent; the inflammatory infiltrate is denser and in some areas obliterates the dermoepidermal junction. It contains numerous plasma cells and foci of leukocytoclasis [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"headingAnchor\" id=\"H34051795\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of seborrheic dermatitis includes psoriasis, rosacea, tinea versicolor, pityriasis rosea, tinea corporis, secondary syphilis, systemic lupus erythematosus (SLE), and pemphigus foliaceous. Most of these conditions can be distinguished clinically; syphilis, SLE, and pemphigus foliaceous require laboratory confirmation. Allergic contact dermatitis may also be considered, particularly when the presentation is atypical or pruritus is significant.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Psoriasis</strong> &ndash; Psoriasis is the main condition in the differential diagnosis of seborrheic dermatitis in adolescents and adults. Sometimes the two diseases may coexist, and the term &quot;sebopsoriasis&quot; has been given to those cases where the distinction cannot be made. Usually, however, psoriatic lesions are sharply demarcated and erythematous, and the scales are more abundant and silvery white (<a href=\"image.htm?imageKey=DERM%2F115750\" class=\"graphic graphic_picture graphicRef115750 \">picture 4</a>). In most cases the extensor areas such as the elbows and knees are involved, although the lesions can occur in the body folds (inverse psoriasis) (<a href=\"image.htm?imageKey=DERM%2F76200\" class=\"graphic graphic_picture graphicRef76200 \">picture 5</a>). Characteristic nail changes (<a href=\"image.htm?imageKey=DERM%2F66374%7EDERM%2F70962\" class=\"graphic graphic_picture graphicRef66374 graphicRef70962 \">picture 6A-B</a>), as well as the presence of arthritis or a positive family history may help establish the diagnosis of psoriasis. (See <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-psoriasis#H9\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of psoriasis&quot;, section on 'Clinical manifestations'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Rosacea</strong> &ndash; Rosacea is another condition that commonly targets the face and sometimes coexists with seborrheic dermatitis. In contrast with seborrheic dermatitis, rosacea shows a predominance of telangiectasias and papulopustules, with frequent involvement of the nose, malar, and perioral areas and minimal or no scaliness (<a href=\"image.htm?imageKey=DERM%2F77020%7EDERM%2F67890%7EDERM%2F78747%7EPC%2F59815%7EDERM%2F56083\" class=\"graphic graphic_picture graphicRef77020 graphicRef67890 graphicRef78747 graphicRef59815 graphicRef56083 \">picture 7A-E</a>). (See <a href=\"topic.htm?path=rosacea-pathogenesis-clinical-features-and-diagnosis#H432867\" class=\"medical medical_review\">&quot;Rosacea: Pathogenesis, clinical features, and diagnosis&quot;, section on 'Clinical features'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Allergic contact dermatitis</strong> &ndash; Allergic contact dermatitis may be suspected in patients with seborrheic dermatitis that does not respond to standard therapy, especially if pruritus is the predominant symptom. Allergic contact dermatitis may occur concurrently or be a complication of seborrheic dermatitis in patients allergic to components of topical medications for seborrheic dermatitis or regular skin and hair care products. Patch testing may be necessary to confirm the diagnosis [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/25\" class=\"abstract_t\">25</a>]. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-allergic-contact-dermatitis\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of allergic contact dermatitis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Tinea versicolor</strong> &ndash; On the trunk, petaloid lesions of seborrheic dermatitis may be mistaken for tinea versicolor, which usually lacks erythema (<a href=\"image.htm?imageKey=PC%2F78860\" class=\"graphic graphic_picture graphicRef78860 \">picture 8</a>). (See <a href=\"topic.htm?path=tinea-versicolor-pityriasis-versicolor#H4\" class=\"medical medical_review\">&quot;Tinea versicolor (Pityriasis versicolor)&quot;, section on 'Clinical features'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pityriasis rosea</strong> &ndash; Pityriasis rosea is distinguished from seborrheic dermatitis by its abrupt onset, presence of a herald patch, and resolution within a few weeks (<a href=\"image.htm?imageKey=DERM%2F87124%7EDERM%2F87126\" class=\"graphic graphic_picture graphicRef87124 graphicRef87126 \">picture 9A-B</a>). The pityriasiform variant of seborrheic dermatitis should be suspected when lesions appear more progressively, persist for more than three months, and are accompanied by lesions on areas usually spared by pityriasis rosea (the face and intertriginous areas). (See <a href=\"topic.htm?path=pityriasis-rosea#H3\" class=\"medical medical_review\">&quot;Pityriasis rosea&quot;, section on 'Clinical features'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Tinea corporis</strong> &ndash; Annular or arciform seborrheic dermatitis lesions on the trunk can be confused with tinea corporis (<a href=\"image.htm?imageKey=PC%2F76839\" class=\"graphic graphic_picture graphicRef76839 \">picture 10</a>); tinea corporis can be ruled out by negative potassium hydroxide (KOH) microscopic examination and negative fungal culture. (See <a href=\"topic.htm?path=dermatophyte-tinea-infections#H23\" class=\"medical medical_review\">&quot;Dermatophyte (tinea) infections&quot;, section on 'Tinea corporis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Secondary syphilis</strong> &ndash; Secondary syphilis, the great imitator, can trigger widespread pityriasiform or psoriasiform eruptions that can be mistaken for seborrheic dermatitis. Additional signs such as palmoplantar and mucosal lesions or peripheral adenopathy should be looked for, and appropriate serologic testing ordered when indicated.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Lupus erythematosus</strong> &ndash; Seborrheic dermatitis of the face may be mistaken for the butterfly eruption of acute systemic lupus erythematosus (SLE) or the discoid plaques of cutaneous LE (<a href=\"image.htm?imageKey=DERM%2F64844%7EDERM%2F75833\" class=\"graphic graphic_picture graphicRef64844 graphicRef75833 \">picture 11A-B</a>). The acute eruption of SLE rarely involves the nasolabial sulcus or crosses the bridge of the nose. Discoid lesions exhibit atrophy and sometimes scarring, along with adherent scales that may have &quot;carpet tacking&quot; on their undersurface (spiny projections that plug dilated follicular openings). Histologic examination and serologic testing for antinuclear autoantibodies should be performed to confirm the diagnosis. (See <a href=\"topic.htm?path=overview-of-cutaneous-lupus-erythematosus\" class=\"medical medical_review\">&quot;Overview of cutaneous lupus erythematosus&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pemphigus foliaceous</strong> &ndash; Pemphigus foliaceous is characterized by erythema, scaling, painful erosions, and crusting that first appear on the face and scalp (<a href=\"image.htm?imageKey=DERM%2F60530%7EDERM%2F54341\" class=\"graphic graphic_picture graphicRef60530 graphicRef54341 \">picture 12A-B</a>) and later involves the chest and back. Histology, direct immunofluorescence, and the measurement of circulating autoantibodies against desmoglein establish the diagnosis. Pemphigus erythematosus of Senear and Usher is a superficial variant of pemphigus foliaceous that is most likely to mimic seborrheic dermatitis. (See <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-pemphigus#H181679733\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of pemphigus&quot;, section on 'Pemphigus foliaceus'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H27253022\"><span class=\"h1\">MANAGEMENT</span></p><p class=\"headingAnchor\" id=\"H1969699911\"><span class=\"h2\">Overview</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Seborrheic dermatitis is a chronic condition. The main goal of therapy is to clear the visible signs of the disease and reduce associated symptoms, such as erythema and pruritus. Repeated or long-term maintenance treatment is often necessary. The available treatments include topical antifungal agents, topical anti-inflammatory agents, and several topical agents with nonspecific antimicrobial, anti-inflammatory, or keratolytic properties. Oral antifungal agents may be a therapeutic option in patients with moderate to severe seborrheic dermatitis that is not adequately controlled with topical therapies. (See <a href=\"#H710057784\" class=\"local\">'Severe or refractory seborrheic dermatitis'</a> below.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Topical antifungals</strong> &ndash; Topical antifungal agents (eg, <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a>, other azoles, <a href=\"topic.htm?path=ciclopirox-drug-information\" class=\"drug drug_general\">ciclopirox</a> olamine) are well established in the treatment of seborrheic dermatitis of the scalp and face because of their ability to decrease the population of <em>Malassezia furfur</em> on the affected skin and their anti-inflammatory property [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/26,27\" class=\"abstract_t\">26,27</a>]. A 2015 systematic review and meta-analysis including 51 randomized trials with over 9000 participants found that in patients with seborrheic dermatitis of the face and scalp, topical ketoconazole 2% applied once or twice daily was more effective than placebo in improving erythema, pruritus, and scaling at four weeks [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/26\" class=\"abstract_t\">26</a>]. In studies comparing topical ketoconazole with topical corticosteroids, both agents had similar efficacy, although topical corticosteroids showed a two-fold greater risk of side effects compared with ketoconazole [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/26\" class=\"abstract_t\">26</a>]. In a small randomized study, the efficacy of a noncorticosteroid combination shampoo containing the antifungal agent piroctone olamine, lactic acid as a keratolytic, and dipotassium glycyrrhizate, a licorice extract with mild anti-inflammatory properties, was compared with that of ketoconazole 1% shampoo in 20 patients with mild to moderate seborrheic dermatitis of the scalp [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/28\" class=\"abstract_t\">28</a>]. Both treatments were found to be equally effective, although the noncorticosteroid product showed better relief of pruritus.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Topical anti-inflammatory agents</strong> &ndash; Topical corticosteroids are widely used for the treatment of seborrheic dermatitis because they reduce inflammation, erythema, and pruritus. Topical calcineurin inhibitors (<a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a> and <a href=\"topic.htm?path=pimecrolimus-drug-information\" class=\"drug drug_general\">pimecrolimus</a>) may be used as an alternative to topical corticosteroids because of their anti-inflammatory properties and lack of adverse effects associated with prolonged use of topical corticosteroids (eg, skin atrophy, telangiectasia) [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/29-33\" class=\"abstract_t\">29-33</a>].</p><p/><p class=\"bulletIndent1\">A 2014 systematic review including 36 randomized trials (2706 participants) found that short-term (&le;4 weeks) treatment with topical corticosteroids (eg <a href=\"topic.htm?path=hydrocortisone-drug-information\" class=\"drug drug_general\">hydrocortisone</a>, <a href=\"topic.htm?path=betamethasone-drug-information\" class=\"drug drug_general\">betamethasone</a>), topical calcineurin inhibitors (ie, <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a>, <a href=\"topic.htm?path=pimecrolimus-drug-information\" class=\"drug drug_general\">pimecrolimus</a>), and topical preparations of <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> salts all reduced the symptoms of seborrheic dermatitis when compared with placebo [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/34\" class=\"abstract_t\">34</a>]. The median rate of total clearance with anti-inflammatory treatments was 53 percent across studies. The frequency of adverse effects, including erythema, burning, dryness, and itching, was similar across all treatment groups. The quality of the included studies was generally low.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Other topical agents</strong> &ndash; Topical agents available over the counter in various vehicles for the treatment of seborrheic dermatitis include <a href=\"topic.htm?path=selenium-sulfide-drug-information\" class=\"drug drug_general\">selenium sulfide</a>, <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> succinate and gluconate, <a href=\"topic.htm?path=zinc-pyrithione-drug-information\" class=\"drug drug_general\">zinc pyrithione</a>, salicylic acid, and <a href=\"topic.htm?path=coal-tar-drug-information\" class=\"drug drug_general\">coal tar</a>.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=selenium-sulfide-drug-information\" class=\"drug drug_general\">Selenium sulfide</a> is a heavy metal salt with antifungal properties. The efficacy of selenium sulfide shampoo for the treatment of seborrheic dermatitis of the scalp has been evaluated in one randomized trial including 149 participants [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/35\" class=\"abstract_t\">35</a>]. In this study, more patients treated with selenium sulfide 2.5% shampoo for four weeks were cleared or had an excellent or good response than those treated with placebo (55 versus 29 percent). Adverse effects of selenium sulfide shampoo include pruritus, burning sensation, and <span class=\"nowrap\">hair/scalp</span> discoloration. Sulfur itself, in the form of precipitated sulfur 3%, colloidal sulfur 5%, or sodium <a href=\"topic.htm?path=sulfacetamide-drug-information\" class=\"drug drug_general\">sulfacetamide</a> 10%, in cream or lotion base, remains an old but effective remedy, although patients may object to its odor [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/36,37\" class=\"abstract_t\">36,37</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Topical <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> sulfate or gluconate (available in Europe but not in the United States) have been shown to be effective in treating seborrheic dermatitis in areas other than the scalp, probably because of their anti-inflammatory properties [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/38-40\" class=\"abstract_t\">38-40</a>]. In a randomized trial, more patients treated with eight weeks of lithium gluconate 8% cream than those treated with <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> 2% cream had improvement in erythema and desquamation (52 versus 30 percent) [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/41\" class=\"abstract_t\">41</a>]. Local irritant reactions have been reported in approximately 10 percent of patients using topical lithium salts.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=zinc-pyrithione-drug-information\" class=\"drug drug_general\">Zinc pyrithione</a> has antibacterial and antifungal properties [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/42\" class=\"abstract_t\">42</a>]. Shampoos containing zinc pyrithione 1% are commonly used to treat dandruff and mild seborrheic dermatitis of the scalp. In one randomized trial including 343 subjects with severe dandruff and seborrheic dermatitis, treatment with <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> 2% shampoo or zinc pyrithione 1% shampoo for four weeks induced improvement in a similar proportion of participants (73 and 67 percent, respectively) [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/43\" class=\"abstract_t\">43</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Shampoos containing salicylic acid and <a href=\"topic.htm?path=coal-tar-drug-information\" class=\"drug drug_general\">coal tar</a> have keratolytic properties and may be helpful in softening thick scales [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/44,45\" class=\"abstract_t\">44,45</a>]. Tar may be combined with <a href=\"topic.htm?path=zinc-pyrithione-drug-information\" class=\"drug drug_general\">zinc pyrithione</a> [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/46\" class=\"abstract_t\">46</a>] or even used under occlusion for refractory seborrheic dermatitis or psoriasis [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/47\" class=\"abstract_t\">47</a>]. As with sulfur, patients may find the odor of tar objectionable or be concerned about its potential carcinogenicity [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/48\" class=\"abstract_t\">48</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Oral antifungal agents</strong> &ndash; Oral antifungal agents, including <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>, <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a>, <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, and <a href=\"topic.htm?path=terbinafine-drug-information\" class=\"drug drug_general\">terbinafine</a>, may be a treatment option for seborrheic dermatitis involving multiple body areas and for recalcitrant dermatitis that is not adequately controlled with topical therapies. However, evidence supporting their use is limited.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A 2014 systematic review including nine uncontrolled, poor-quality studies evaluating oral <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> for seborrheic dermatitis found that itraconazole was effective in inducing clinical improvement and mycologic cure in 59 to 93 percent and 40 to 86 percent of patients, respectively [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/49\" class=\"abstract_t\">49</a>]. The regimen most frequently used involved the oral administration of itraconazole 200 mg per day for seven days followed by varying intermittent therapy for 2 to 11 months.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In a randomized trial, 68 patients with moderate to severe seborrheic dermatitis received topical 1% <a href=\"topic.htm?path=hydrocortisone-drug-information\" class=\"drug drug_general\">hydrocortisone</a> ointment once daily and 2% <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> cream twice daily plus either oral <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> 200 <span class=\"nowrap\">mg/day</span> or placebo for one week, followed by a maintenance treatment with oral itraconazole 200 <span class=\"nowrap\">mg/day</span> or placebo given on the first two days of the following three months [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/50\" class=\"abstract_t\">50</a>]. At four months, 10 patients in the itraconazole group, but none in the placebo group, achieved complete clearing; moderate to marked improvement was reported in 65 and 79 percent of patients in the itraconazole and placebo groups, respectively.</p><p/><p class=\"headingAnchor\" id=\"H1431767\"><span class=\"h2\">Seborrheic dermatitis of the scalp</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with mild seborrheic dermatitis of the scalp who have diffuse, fine desquamation without inflammation (dandruff), we suggest treatment with an antifungal shampoo. Antifungal shampoos include <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> 2% and <a href=\"topic.htm?path=ciclopirox-drug-information\" class=\"drug drug_general\">ciclopirox</a> 1%, available by prescription, and <a href=\"topic.htm?path=zinc-pyrithione-drug-information\" class=\"drug drug_general\">zinc pyrithione</a> 1% and <a href=\"topic.htm?path=selenium-sulfide-drug-information\" class=\"drug drug_general\">selenium sulfide</a> 2.5% shampoo, available over the counter.</p><p>The shampoo should be left on for 5 to 10 minutes before rinsing off. The medicated shampoo should be used frequently (daily or at least two or three times per week) for several weeks, until remission is achieved. Subsequently, the use of the medicated shampoo once a week may be helpful to prevent relapse [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/51\" class=\"abstract_t\">51</a>]. Minor adverse effects, such as irritation <span class=\"nowrap\">and/or</span> burning sensation, are common with antifungal shampoo [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/35,52\" class=\"abstract_t\">35,52</a>].</p><p>Patients sometimes complain that their shampoo is no longer effective. Given that some strains of <em>Malassezia</em> eventually become resistant to azole antifungals [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/19\" class=\"abstract_t\">19</a>], it may be wise to effectuate, every few weeks to months, a rotation among shampoos based on different molecules.</p><p>For patients with moderate to severe seborrheic dermatitis of the scalp who have scale, inflammation, and pruritus, we suggest treatment with an antifungal shampoo (eg, <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> 2% shampoo) in combination with a high-potency topical corticosteroid (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 1</a>) in a formulation (lotion, spray aerosol, or foam) of patient choice. Topical corticosteroids can be used daily for two to four weeks.</p><p>The addition of a salicylic acid shampoo to the above regimen may be helpful for patients with thick scale.</p><p class=\"headingAnchor\" id=\"H43690674\"><span class=\"h2\">Seborrheic dermatitis of the face</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with seborrheic dermatitis of the face, we suggest treatment with a low-potency topical corticosteroid cream (group 7 or 6 (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 1</a>)), a topical antifungal agent (<a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> 2% cream, other azole creams, or <a href=\"topic.htm?path=ciclopirox-drug-information\" class=\"drug drug_general\">ciclopirox</a> 1% cream, (<a href=\"image.htm?imageKey=PC%2F76148\" class=\"graphic graphic_table graphicRef76148 \">table 2</a>)), or a combination of the two. The topical corticosteroid cream is applied to the affected areas once or twice daily only until symptoms subside to avoid potential adverse effects associated with prolonged use of topical corticosteroids on the face. (See <a href=\"topic.htm?path=general-principles-of-dermatologic-therapy-and-topical-corticosteroid-use#H16\" class=\"medical medical_review\">&quot;General principles of dermatologic therapy and topical corticosteroid use&quot;, section on 'Side effects'</a>.)</p><p>Topical calcineurin inhibitors (<a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a> 0.1% ointment and <a href=\"topic.htm?path=pimecrolimus-drug-information\" class=\"drug drug_general\">pimecrolimus</a> 1% cream) may be used as an alternative to topical corticosteroids for the treatment of facial seborrheic dermatitis [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/32,53,54\" class=\"abstract_t\">32,53,54</a>]. <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">Lithium</a> succinate and lithium gluconate cream or gel are available in Europe and have been shown to be effective in treating seborrheic dermatitis in areas other than the scalp [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/38-40\" class=\"abstract_t\">38-40</a>].</p><p>For men with seborrheic dermatitis of the face who have mustaches and beards, we suggest <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> 2% shampooing of the facial hair daily until remission and then once per week. A low-potency corticosteroid (group 7 (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 1</a>)) can be added to the initial treatment to control inflammation and itching.</p><p class=\"headingAnchor\" id=\"H1666176\"><span class=\"h2\">Seborrheic blepharitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The management of blepharitis, including seborrheic blepharitis, is discussed separately. (See <a href=\"topic.htm?path=blepharitis#H21\" class=\"medical medical_review\">&quot;Blepharitis&quot;, section on 'Management'</a>.)</p><p class=\"headingAnchor\" id=\"H43690682\"><span class=\"h2\">Seborrheic dermatitis of the trunk and intertriginous areas</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with seborrheic dermatitis of the trunk and intertriginous areas, we suggest treatment with topical antifungal agents, topical corticosteroid creams, or a combination of the two. A low-potency topical corticosteroid cream should be used in the intertriginous areas; medium-potency topical corticosteroids (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 1</a>) can be used for seborrheic dermatitis involving the chest or the upper back. The topical corticosteroid cream is applied to the affected areas once or twice daily only until symptoms subside to avoid potential adverse effects.</p><p>Alternative topical antifungal agents include <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> 2% cream, other azole creams, and <a href=\"topic.htm?path=ciclopirox-drug-information\" class=\"drug drug_general\">ciclopirox</a> cream. Topical antifungal agents are applied to affected areas once or twice daily until symptoms subside. Adverse effects are uncommon with topical antifungal agents.</p><p class=\"headingAnchor\" id=\"H1431820\"><span class=\"h2\">Seborrheic dermatitis in patients with HIV infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Seborrheic dermatitis is more diffuse and severe in human immunodeficiency virus (HIV)-positive patients and may require a prolonged course of treatment. There are no studies evaluating the treatment of seborrheic dermatitis in HIV-positive patients. Initial management is the same as for patients who are not HIV-positive [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/55,56\" class=\"abstract_t\">55,56</a>]. In severe cases or in cases that are refractory to topical treatment, a course of oral <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> (200 <span class=\"nowrap\">mg/day</span> orally for one week) may be warranted.</p><p class=\"headingAnchor\" id=\"H710057784\"><span class=\"h2\">Severe or refractory seborrheic dermatitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is little evidence to guide treatment of severe or refractory seborrheic dermatitis in non-HIV-positive patients. Agents that have been used in observational studies or small randomized trials include oral <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a>, <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>, <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, and <a href=\"topic.htm?path=terbinafine-drug-information\" class=\"drug drug_general\">terbinafine</a> [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/49,50\" class=\"abstract_t\">49,50</a>]. Among these, we suggest oral itraconazole. Oral itraconazole is given at the dose of 200 mg per day for seven days.</p><p>Whenever apparent seborrheic dermatitis does not respond to appropriate therapy, the diagnosis should be reconsidered. (See <a href=\"#H34051795\" class=\"local\">'Differential diagnosis'</a> above.)</p><p class=\"headingAnchor\" id=\"H2907239957\"><span class=\"h2\">Coexistent seborrheic dermatitis and rosacea</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with coexistent facial seborrheic dermatitis and rosacea, adequate treatment of both conditions may be difficult. Prolonged use of even mild topical corticosteroids prescribed for seborrheic dermatitis may exacerbate rosacea and should ideally be avoided or used very sparingly and intermittently. By contrast, topical <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a> 1% gel or cream, used for rosacea, may also help mild seborrheic dermatitis. In patients who have papulopustular rosacea and facial seborrheic dermatitis, topical <a href=\"topic.htm?path=azelaic-acid-drug-information\" class=\"drug drug_general\">azelaic acid</a>, which has antibacterial and antifungal properties, has been suggested as a treatment option for both conditions [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/57\" class=\"abstract_t\">57</a>]. (See <a href=\"topic.htm?path=management-of-rosacea#H2325386\" class=\"medical medical_review\">&quot;Management of rosacea&quot;, section on 'Topical azelaic acid'</a>.)</p><p class=\"headingAnchor\" id=\"H364614144\"><span class=\"h1\">PREVENTION OF RELAPSE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For most patients with seborrheic dermatitis, we suggest intermittent use of topical therapies to prevent relapse. <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">Ketoconazole</a> 2% shampoo and <a href=\"topic.htm?path=ciclopirox-drug-information\" class=\"drug drug_general\">ciclopirox</a> 1% shampoo, used intermittently, have been shown to be effective in preventing relapses of scalp seborrheic dermatitis [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/51,58\" class=\"abstract_t\">51,58</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a six-month trial in which 312 patients who responded to initial treatment of scalp seborrheic dermatitis were randomly assigned to <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> 2% shampoo once weekly, every two weeks, or placebo, relapses were observed in 19, 31, and 47 percent of the patients, respectively [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/58\" class=\"abstract_t\">58</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a similar study in which 428 patients were randomly assigned to four months of treatment with <a href=\"topic.htm?path=ciclopirox-drug-information\" class=\"drug drug_general\">ciclopirox</a> shampoo once weekly, every two weeks, or placebo, the relapse rates were 15, 22, and 35 percent, respectively [<a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/51\" class=\"abstract_t\">51</a>].</p><p/><p>The prevention of relapse of seborrheic dermatitis of the face, trunk, and intertriginous areas has not been well studied. However, it is common practice to use antifungal cream or <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> 2% shampoo (as facial or body wash) intermittently to prevent relapse. The risk of side effects with this approach is minimal.</p><p class=\"headingAnchor\" id=\"H827171841\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-seborrheic-dermatitis\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Seborrheic dermatitis&quot;</a>.) </p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topic (see <a href=\"topic.htm?path=seborrheic-dermatitis-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Seborrheic dermatitis (The Basics)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=seborrheic-dermatitis-including-dandruff-and-cradle-cap-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Seborrheic dermatitis (including dandruff and cradle cap) (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H1666197\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Seborrheic dermatitis is a chronic, relapsing, and usually mild form of dermatitis of unknown origin occurring in areas rich in sebaceous glands (scalp, face, upper trunk, intertriginous areas); indirect evidence supports a pathogenetic role for the <em>Malassezia</em> yeast. (See <a href=\"#H34051766\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The mildest and most common form of scalp seborrheic dermatitis is dandruff, a fine, white, diffuse scaliness of the scalp without underlying erythema (<a href=\"image.htm?imageKey=DERM%2F54173\" class=\"graphic graphic_picture graphicRef54173 \">picture 2</a>). Manifestations of severe seborrheic dermatitis of the scalp (<a href=\"image.htm?imageKey=DERM%2F76985%7EDERM%2F114660%7EDERM%2F114661\" class=\"graphic graphic_picture graphicRef76985 graphicRef114660 graphicRef114661 \">picture 3A-C</a>) or other body sites include inflamed, erythematous plaques covered with yellowish, greasy scales (<a href=\"image.htm?imageKey=DERM%2F59104%7EDERM%2F65167%7EDERM%2F53407\" class=\"graphic graphic_picture graphicRef59104 graphicRef65167 graphicRef53407 \">picture 1C, 1E-F</a>). (See <a href=\"#H34051773\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of seborrheic dermatitis is usually made clinically based on the appearance and location of the lesions. The differential diagnosis includes psoriasis (<a href=\"image.htm?imageKey=DERM%2F115750\" class=\"graphic graphic_picture graphicRef115750 \">picture 4</a>), rosacea (<a href=\"image.htm?imageKey=DERM%2F77020%7EDERM%2F67890%7EDERM%2F78747%7EPC%2F59815%7EDERM%2F56083\" class=\"graphic graphic_picture graphicRef77020 graphicRef67890 graphicRef78747 graphicRef59815 graphicRef56083 \">picture 7A-E</a>), tinea versicolor (<a href=\"image.htm?imageKey=PC%2F78860\" class=\"graphic graphic_picture graphicRef78860 \">picture 8</a>), pityriasis rosea (<a href=\"image.htm?imageKey=DERM%2F87126%7EDERM%2F87124\" class=\"graphic graphic_picture graphicRef87126 graphicRef87124 \">picture 9A-B</a>), tinea corporis (<a href=\"image.htm?imageKey=PC%2F76839\" class=\"graphic graphic_picture graphicRef76839 \">picture 10</a>), secondary syphilis, lupus erythematosus (<a href=\"image.htm?imageKey=DERM%2F64844%7EDERM%2F75833\" class=\"graphic graphic_picture graphicRef64844 graphicRef75833 \">picture 11A-B</a>), and pemphigus foliaceous (<a href=\"image.htm?imageKey=DERM%2F60530%7EDERM%2F54341\" class=\"graphic graphic_picture graphicRef60530 graphicRef54341 \">picture 12A-B</a>). These conditions can be differentiated clinically <span class=\"nowrap\">and/or</span> through laboratory tests and histology. (See <a href=\"#H710057309\" class=\"local\">'Diagnosis'</a> above and <a href=\"#H34051795\" class=\"local\">'Differential diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with mild seborrheic dermatitis of the scalp without inflammation (dandruff), we suggest treatment with antifungal shampoos (<a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> 2%, <a href=\"topic.htm?path=ciclopirox-drug-information\" class=\"drug drug_general\">ciclopirox</a> 1%) (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). Alternative medicated fungal shampoos available over the counter include <a href=\"topic.htm?path=zinc-pyrithione-drug-information\" class=\"drug drug_general\">zinc pyrithione</a> 1% and <a href=\"topic.htm?path=selenium-sulfide-drug-information\" class=\"drug drug_general\">selenium sulfide</a> 2.5%. The medicated shampoo should be used frequently (daily or at least two or three times per week) for several weeks, until remission is achieved. (See <a href=\"#H1431767\" class=\"local\">'Seborrheic dermatitis of the scalp'</a> above.)</p><p/><p class=\"bulletIndent1\">For patients with moderate to severe seborrheic dermatitis of the scalp who have scale, inflammation, and pruritus, we suggest treatment with an antifungal shampoo (eg, <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> 2% shampoo) in combination with a high-potency topical corticosteroid (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 1</a>) in a formulation (lotion, spray, foam) of patient choice (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). The topical corticosteroid can be used once daily for two to four weeks. (See <a href=\"#H1431767\" class=\"local\">'Seborrheic dermatitis of the scalp'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with seborrheic dermatitis of the face, we suggest treatment with low-potency topical corticosteroid cream (groups 6 or 7 (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 1</a>)), topical antifungal agent (<a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> 2% cream, other azole creams, or <a href=\"topic.htm?path=ciclopirox-drug-information\" class=\"drug drug_general\">ciclopirox</a> 1% cream (<a href=\"image.htm?imageKey=PC%2F76148\" class=\"graphic graphic_table graphicRef76148 \">table 2</a>)), or a combination of the two (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). The topical therapy is applied to the affected areas once or twice daily only until symptoms subside. (See <a href=\"#H43690674\" class=\"local\">'Seborrheic dermatitis of the face'</a> above.)</p><p/><p class=\"bulletIndent1\">For men with seborrheic dermatitis of the face who have mustaches and beards, we suggest <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> 2% shampooing of the facial hair (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). The shampoo is used daily until remission and then once per week. A low-potency corticosteroid (group 7 (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 1</a>)) can be added to the initial treatment to control inflammation and itching.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with seborrheic dermatitis of the trunk and intertriginous areas, we suggest treatment with low-potency (groups 6 or 7) topical corticosteroid cream (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 1</a>), topical antifungal agents, or a combination of the two (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). The topical therapy is applied to the affected areas once or twice daily only until symptoms subside.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For most patients with seborrheic dermatitis, intermittent use of topical therapies may be helpful to prevent relapse (see <a href=\"#H364614144\" class=\"local\">'Prevention of relapse'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">Ketoconazole</a> 2% shampoo or <a href=\"topic.htm?path=ciclopirox-drug-information\" class=\"drug drug_general\">ciclopirox</a> 1% shampoo once per week for seborrheic dermatitis of the scalp.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">Ketoconazole</a> 2% shampoo (as facial or body wash) or ketoconazole 2% cream, other azole cream, or <a href=\"topic.htm?path=ciclopirox-drug-information\" class=\"drug drug_general\">ciclopirox</a> 1% cream once per week for seborrheic dermatitis of the face, trunk, and intertriginous areas.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">Johnson MLT. Skin Conditions and Related Need for Medical Care among Persons 1&ndash;74 Years, United States, 1971&ndash;1974. Series 11, Data from the National Health Survey November, No. 212, DHEW Pub No. (PHS) 79&ndash;1660. U.S. Department of Health, Education, and Welfare, Public Health Service, National Center for Health, Hyattsville, MD 1978.</li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/2\" class=\"nounderline abstract_t\">Berger RS, Stoner MF, Hobbs ER, et al. Cutaneous manifestations of early human immunodeficiency virus exposure. J Am Acad Dermatol 1988; 19:298.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/3\" class=\"nounderline abstract_t\">Soeprono FF, Schinella RA, Cockerell CJ, Comite SL. Seborrheic-like dermatitis of acquired immunodeficiency syndrome. A clinicopathologic study. J Am Acad Dermatol 1986; 14:242.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/4\" class=\"nounderline abstract_t\">Burton JL, Cartlidge M, Shuster S. Effect of L-dopa on the seborrhoea of Parkinsonism. Br J Dermatol 1973; 88:475.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/5\" class=\"nounderline abstract_t\">Kohn SR, Pochi PE, Strauss JS, et al. Sebaceous gland secretion in Parkinson's disease during L-dopa treatment. J Invest Dermatol 1973; 60:134.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/6\" class=\"nounderline abstract_t\">Burton JL, Pye RJ. Seborrhoea is not a feature of seborrhoeic dermatitis. Br Med J (Clin Res Ed) 1983; 286:1169.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/7\" class=\"nounderline abstract_t\">McGinley KJ, Leyden JJ, Marples RR, Kligman AM. Quantitative microbiology of the scalp in non-dandruff, dandruff, and seborrheic dermatitis. J Invest Dermatol 1975; 64:401.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/8\" class=\"nounderline abstract_t\">Heng MC, Henderson CL, Barker DC, Haberfelde G. Correlation of Pityosporum ovale density with clinical severity of seborrheic dermatitis as assessed by a simplified technique. J Am Acad Dermatol 1990; 23:82.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/9\" class=\"nounderline abstract_t\">Amado Y, Pati&ntilde;o-Uzc&aacute;tegui A, Cepero de Garc&iacute;a MC, et al. Seborrheic dermatitis: predisposing factors and ITS2 secondary structure for Malassezia phylogenic analysis. Med Mycol 2013; 51:868.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/10\" class=\"nounderline abstract_t\">Kim SY, Kim SH, Kim SN, et al. Isolation and identification of Malassezia species from Chinese and Korean patients with seborrheic dermatitis and in vitro studies on their bioactivity on sebaceous lipids and IL-8 production. Mycoses 2016; 59:274.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/11\" class=\"nounderline abstract_t\">Gupta AK, Kohli Y, Summerbell RC, Faergemann J. Quantitative culture of Malassezia species from different body sites of individuals with or without dermatoses. Med Mycol 2001; 39:243.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/12\" class=\"nounderline abstract_t\">Pech&egrave;re M, Krischer J, Remondat C, et al. Malassezia spp carriage in patients with seborrheic dermatitis. J Dermatol 1999; 26:558.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/13\" class=\"nounderline abstract_t\">Sandstr&ouml;m Falk MH, Tengvall Linder M, Johansson C, et al. The prevalence of Malassezia yeasts in patients with atopic dermatitis, seborrhoeic dermatitis and healthy controls. Acta Derm Venereol 2005; 85:17.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/14\" class=\"nounderline abstract_t\">Arsic Arsenijevic VS, Milobratovic D, Barac AM, et al. A laboratory-based study on patients with Parkinson's disease and seborrheic dermatitis: the presence and density of Malassezia yeasts, their different species and enzymes production. BMC Dermatol 2014; 14:5.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/15\" class=\"nounderline abstract_t\">Paulino LC. New perspectives on dandruff and seborrheic dermatitis: lessons we learned from bacterial and fungal skin microbiota. Eur J Dermatol 2017; 27:4.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/16\" class=\"nounderline abstract_t\">Faergemann J, Bergbrant IM, Dohs&eacute; M, et al. Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol 2001; 144:549.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/17\" class=\"nounderline abstract_t\">Riciputo RM, Oliveri S, Micali G, Sapuppo A. Phospholipase activity in Malassezia furfur pathogenic strains. Mycoses 1996; 39:233.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/18\" class=\"nounderline abstract_t\">Parry ME, Sharpe GR. Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast. Br J Dermatol 1998; 139:254.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/19\" class=\"nounderline abstract_t\">Dessinioti C, Katsambas A. Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies. Clin Dermatol 2013; 31:343.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/20\" class=\"nounderline abstract_t\">Mathes BM, Douglass MC. Seborrheic dermatitis in patients with acquired immunodeficiency syndrome. J Am Acad Dermatol 1985; 13:947.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/21\" class=\"nounderline abstract_t\">Naldi L, Rebora A. Clinical practice. Seborrheic dermatitis. N Engl J Med 2009; 360:387.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/22\" class=\"nounderline abstract_t\">Mu&ntilde;oz-P&eacute;rez MA, Rodriguez-Pichardo A, Camacho F, Colmenero MA. Dermatological findings correlated with CD4 lymphocyte counts in a prospective 3 year study of 1161 patients with human immunodeficiency virus disease predominantly acquired through intravenous drug abuse. Br J Dermatol 1998; 139:33.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/23\" class=\"nounderline abstract_t\">Osei-Sekyere B, Karstaedt AS. Immune reconstitution inflammatory syndrome involving the skin. Clin Exp Dermatol 2010; 35:477.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/24\" class=\"nounderline abstract_t\">Tegner E. Seborrhoeic dermatitis of the face induced by PUVA treatment. Acta Derm Venereol 1983; 63:335.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/25\" class=\"nounderline abstract_t\">Ljubojevic S, Lipozencic J, Basta-Juzbasic A. Contact allergy to corticosteroids and Malassezia furfur in seborrhoeic dermatitis patients. J Eur Acad Dermatol Venereol 2011; 25:647.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/26\" class=\"nounderline abstract_t\">Okokon EO, Verbeek JH, Ruotsalainen JH, et al. Topical antifungals for seborrhoeic dermatitis. Cochrane Database Syst Rev 2015; :CD008138.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/27\" class=\"nounderline abstract_t\">Apasrawirote W, Udompataikul M, Rattanamongkolgul S. Topical antifungal agents for seborrheic dermatitis: systematic review and meta-analysis. J Med Assoc Thai 2011; 94:756.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/28\" class=\"nounderline abstract_t\">Dall'Oglio F, Lacarrubba F, Verz&igrave; AE, Micali G. Noncorticosteroid Combination Shampoo versus 1% Ketoconazole Shampoo for the Management of Mild-to-Moderate Seborrheic Dermatitis of the Scalp: Results from a Randomized, Investigator-Single-Blind Trial Using Clinical and Trichoscopic Evaluation. Skin Appendage Disord 2016; 1:126.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/29\" class=\"nounderline abstract_t\">Warshaw EM, Wohlhuter RJ, Liu A, et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol 2007; 57:257.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/30\" class=\"nounderline abstract_t\">Firooz A, Solhpour A, Gorouhi F, et al. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol 2006; 142:1066.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/31\" class=\"nounderline abstract_t\">Koc E, Arca E, Kose O, Akar A. An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis. J Dermatolog Treat 2009; 20:4.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/32\" class=\"nounderline abstract_t\">Papp KA, Papp A, Dahmer B, Clark CS. Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults. J Am Acad Dermatol 2012; 67:e11.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/33\" class=\"nounderline abstract_t\">Gupta AK, Versteeg SG. Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review. Am J Clin Dermatol 2017; 18:193.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/34\" class=\"nounderline abstract_t\">Kastarinen H, Oksanen T, Okokon EO, et al. Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp. Cochrane Database Syst Rev 2014; :CD009446.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/35\" class=\"nounderline abstract_t\">Danby FW, Maddin WS, Margesson LJ, Rosenthal D. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol 1993; 29:1008.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/36\" class=\"nounderline abstract_t\">Gupta AK, Nicol K. The use of sulfur in dermatology. J Drugs Dermatol 2004; 3:427.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/37\" class=\"nounderline abstract_t\">Olansky S. Old drug--in a new system--revisited. Cutis 1977; 19:852.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/38\" class=\"nounderline abstract_t\">Ballanger F, Tenaud I, Volteau C, et al. Anti-inflammatory effects of lithium gluconate on keratinocytes: a possible explanation for efficiency in seborrhoeic dermatitis. Arch Dermatol Res 2008; 300:215.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/39\" class=\"nounderline abstract_t\">Dreno B, Moyse D. Lithium gluconate in the treatment of seborrhoeic dermatitis: a multicenter, randomised, double-blind study versus placebo. Eur J Dermatol 2002; 12:549.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/40\" class=\"nounderline abstract_t\">A double-blind, placebo-controlled, multicenter trial of lithium succinate ointment in the treatment of seborrheic dermatitis. Efalith Multicenter Trial Group. J Am Acad Dermatol 1992; 26:452.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/41\" class=\"nounderline abstract_t\">Dreno B, Chosidow O, Revuz J, et al. Lithium gluconate 8% vs ketoconazole 2% in the treatment of seborrhoeic dermatitis: a multicentre, randomized study. Br J Dermatol 2003; 148:1230.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/42\" class=\"nounderline abstract_t\">Schwartz JR. Zinc Pyrithione: A Topical Antimicrobial With Complex Pharmaceutics. J Drugs Dermatol 2016; 15:140.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/43\" class=\"nounderline abstract_t\">Pi&eacute;rard-Franchimont C, Goffin V, Decroix J, Pi&eacute;rard GE. A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol Appl Skin Physiol 2002; 15:434.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/44\" class=\"nounderline abstract_t\">Pi&eacute;rard-Franchimont C, Pi&eacute;rard GE, Vroome V, et al. Comparative anti-dandruff efficacy between a tar and a non-tar shampoo. Dermatology 2000; 200:181.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/45\" class=\"nounderline abstract_t\">Squire RA, Goode K. A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. J Dermatolog Treat 2002; 13:51.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/46\" class=\"nounderline abstract_t\">Veien NK, Pilgaard CE, Gade M. Seborrhoeic dermatitis of the scalp treated with a tar/zinc pyrithione shampoo. Clin Exp Dermatol 1980; 5:53.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/47\" class=\"nounderline abstract_t\">Garcia RL, Miller JD, Miller WN. Occlusive tar extract therapy for recalcitrant psoriasis and seborrheic dermatitis of the scalp. Cutis 1978; 22:90.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/48\" class=\"nounderline abstract_t\">Goldman WJ. Carcinogenicity of coal-tar shampoo. Lancet 1995; 345:326.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/49\" class=\"nounderline abstract_t\">Gupta AK, Richardson M, Paquet M. Systematic review of oral treatments for seborrheic dermatitis. J Eur Acad Dermatol Venereol 2014; 28:16.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/50\" class=\"nounderline abstract_t\">Ghodsi SZ, Abbas Z, Abedeni R. Efficacy of Oral Itraconazole in the Treatment and Relapse Prevention of Moderate to Severe Seborrheic Dermatitis: A Randomized, Placebo-Controlled Trial. Am J Clin Dermatol 2015; 16:431.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/51\" class=\"nounderline abstract_t\">Shuster S, Meynadier J, Kerl H, Nolting S. Treatment and prophylaxis of seborrheic dermatitis of the scalp with antipityrosporal 1% ciclopirox shampoo. Arch Dermatol 2005; 141:47.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/52\" class=\"nounderline abstract_t\">Lebwohl M, Plott T. Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial. Int J Dermatol 2004; 43 Suppl 1:17.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/53\" class=\"nounderline abstract_t\">Kim TW, Mun JH, Jwa SW, et al. Proactive treatment of adult facial seborrhoeic dermatitis with 0.1% tacrolimus ointment: randomized, double-blind, vehicle-controlled, multi-centre trial. Acta Derm Venereol 2013; 93:557.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/54\" class=\"nounderline abstract_t\">Ang-Tiu CU, Meghrajani CF, Maano CC. Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials. Expert Rev Clin Pharmacol 2012; 5:91.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/55\" class=\"nounderline abstract_t\">Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol 2004; 18:13.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/56\" class=\"nounderline abstract_t\">Osborne GE, Taylor C, Fuller LC. The management of HIV-related skin disease. Part II: neoplasms and inflammatory disorders. Int J STD AIDS 2003; 14:235.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/57\" class=\"nounderline abstract_t\">McFalda WL, Roebuck HL. Rational management of papulopustular rosacea with concomitant facial seborrheic dermatitis: a case report. J Clin Aesthet Dermatol 2011; 4:40.</a></li><li><a href=\"https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults/abstract/58\" class=\"nounderline abstract_t\">Peter RU, Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. Br J Dermatol 1995; 132:441.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 13669 Version 26.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1666197\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H34051752\" id=\"outline-link-H34051752\">INTRODUCTION</a></li><li><a href=\"#H34051759\" id=\"outline-link-H34051759\">EPIDEMIOLOGY</a></li><li><a href=\"#H34051766\" id=\"outline-link-H34051766\">PATHOGENESIS</a></li><li><a href=\"#H34051773\" id=\"outline-link-H34051773\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H498821253\" id=\"outline-link-H498821253\">Scalp</a></li><li><a href=\"#H498821260\" id=\"outline-link-H498821260\">Face</a></li><li><a href=\"#H498821267\" id=\"outline-link-H498821267\">Periocular</a></li><li><a href=\"#H498821274\" id=\"outline-link-H498821274\">Trunk</a></li><li><a href=\"#H498821343\" id=\"outline-link-H498821343\">In patients with human immunodeficiency virus</a></li></ul></li><li><a href=\"#H498821317\" id=\"outline-link-H498821317\">CLINICAL COURSE</a></li><li><a href=\"#H710057309\" id=\"outline-link-H710057309\">DIAGNOSIS</a><ul><li><a href=\"#H34051788\" id=\"outline-link-H34051788\">Histopathology</a></li></ul></li><li><a href=\"#H34051795\" id=\"outline-link-H34051795\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H27253022\" id=\"outline-link-H27253022\">MANAGEMENT</a><ul><li><a href=\"#H1969699911\" id=\"outline-link-H1969699911\">Overview</a></li><li><a href=\"#H1431767\" id=\"outline-link-H1431767\">Seborrheic dermatitis of the scalp</a></li><li><a href=\"#H43690674\" id=\"outline-link-H43690674\">Seborrheic dermatitis of the face</a></li><li><a href=\"#H1666176\" id=\"outline-link-H1666176\">Seborrheic blepharitis</a></li><li><a href=\"#H43690682\" id=\"outline-link-H43690682\">Seborrheic dermatitis of the trunk and intertriginous areas</a></li><li><a href=\"#H1431820\" id=\"outline-link-H1431820\">Seborrheic dermatitis in patients with HIV infection</a></li><li><a href=\"#H710057784\" id=\"outline-link-H710057784\">Severe or refractory seborrheic dermatitis</a></li><li><a href=\"#H2907239957\" id=\"outline-link-H2907239957\">Coexistent seborrheic dermatitis and rosacea</a></li></ul></li><li><a href=\"#H364614144\" id=\"outline-link-H364614144\">PREVENTION OF RELAPSE</a></li><li><a href=\"#H827171841\" id=\"outline-link-H827171841\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H13010789\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H1666197\" id=\"outline-link-H1666197\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/13669|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/56410\" class=\"graphic graphic_picture\">- Seborrheic dermatitis face</a></li><li><a href=\"image.htm?imageKey=DERM/82073\" class=\"graphic graphic_picture\">- Seborrheic dermatitis ear</a></li><li><a href=\"image.htm?imageKey=DERM/59104\" class=\"graphic graphic_picture\">- Seborrheic dermatitis face 2</a></li><li><a href=\"image.htm?imageKey=DERM/54173\" class=\"graphic graphic_picture\">- Seborrheic dermatitis scalp</a></li><li><a href=\"image.htm?imageKey=DERM/76985\" class=\"graphic graphic_picture\">- Seborrheic dermatitis scalp 2</a></li><li><a href=\"image.htm?imageKey=DERM/114660\" class=\"graphic graphic_picture\">- Seborrheic dermatitis scalp dark skin</a></li><li><a href=\"image.htm?imageKey=DERM/114661\" class=\"graphic graphic_picture\">- Pityriasis amiantacea 2</a></li><li><a href=\"image.htm?imageKey=DERM/114634\" class=\"graphic graphic_picture\">- Seborrheic dermatitis dark skin 2</a></li><li><a href=\"image.htm?imageKey=DERM/65167\" class=\"graphic graphic_picture\">- Seborrheic dermatitis face 3</a></li><li><a href=\"image.htm?imageKey=DERM/53407\" class=\"graphic graphic_picture\">- Seborrheic dermatitis axilla</a></li><li><a href=\"image.htm?imageKey=DERM/115750\" class=\"graphic graphic_picture\">- Plaque type psoriasis</a></li><li><a href=\"image.htm?imageKey=DERM/76200\" class=\"graphic graphic_picture\">- Inverse psoriasis groin</a></li><li><a href=\"image.htm?imageKey=DERM/66374\" class=\"graphic graphic_picture\">- Nail psoriasis oil drop</a></li><li><a href=\"image.htm?imageKey=DERM/70962\" class=\"graphic graphic_picture\">- Nail psoriasis pits</a></li><li><a href=\"image.htm?imageKey=DERM/77020\" class=\"graphic graphic_picture\">- Rosacea erythema</a></li><li><a href=\"image.htm?imageKey=DERM/67890\" class=\"graphic graphic_picture\">- Rosacea papules</a></li><li><a href=\"image.htm?imageKey=DERM/78747\" class=\"graphic graphic_picture\">- Rosacea papules and pustules</a></li><li><a href=\"image.htm?imageKey=PC/59815\" class=\"graphic graphic_picture\">- Rosacea with papules</a></li><li><a href=\"image.htm?imageKey=DERM/56083\" class=\"graphic graphic_picture\">- Rosacea erythema cheek</a></li><li><a href=\"image.htm?imageKey=PC/78860\" class=\"graphic graphic_picture\">- Tinea versicolor chest</a></li><li><a href=\"image.htm?imageKey=DERM/87124\" class=\"graphic graphic_picture\">- Pityriasis rosea on abdomen</a></li><li><a href=\"image.htm?imageKey=DERM/87126\" class=\"graphic graphic_picture\">- Pityriasis rosea with herald patch</a></li><li><a href=\"image.htm?imageKey=PC/76839\" class=\"graphic graphic_picture\">- Tinea corporis 4</a></li><li><a href=\"image.htm?imageKey=DERM/64844\" class=\"graphic graphic_picture\">- Discoid lupus - right cheek</a></li><li><a href=\"image.htm?imageKey=DERM/75833\" class=\"graphic graphic_picture\">- Discoid lupus - left ear</a></li><li><a href=\"image.htm?imageKey=DERM/60530\" class=\"graphic graphic_picture\">- Pemphigus foliaceus scalp</a></li><li><a href=\"image.htm?imageKey=DERM/54341\" class=\"graphic graphic_picture\">- Pemphigus foliaceus face</a></li></ul></li><li><div id=\"DERM/13669|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/62402\" class=\"graphic graphic_table\">- Topical corticosteroids</a></li><li><a href=\"image.htm?imageKey=PC/76148\" class=\"graphic graphic_table\">- Topical antifungal agents</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=blepharitis\" class=\"medical medical_review\">Blepharitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-allergic-contact-dermatitis\" class=\"medical medical_review\">Clinical features and diagnosis of allergic contact dermatitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-parkinson-disease\" class=\"medical medical_review\">Clinical manifestations of Parkinson disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cradle-cap-and-seborrheic-dermatitis-in-infants\" class=\"medical medical_review\">Cradle cap and seborrheic dermatitis in infants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dermatophyte-tinea-infections\" class=\"medical medical_review\">Dermatophyte (tinea) infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-psoriasis\" class=\"medical medical_review\">Epidemiology, clinical manifestations, and diagnosis of psoriasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=external-otitis-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">External otitis: Pathogenesis, clinical features, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=general-principles-of-dermatologic-therapy-and-topical-corticosteroid-use\" class=\"medical medical_review\">General principles of dermatologic therapy and topical corticosteroid use</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=immune-reconstitution-inflammatory-syndrome\" class=\"medical medical_review\">Immune reconstitution inflammatory syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-rosacea\" class=\"medical medical_review\">Management of rosacea</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-cutaneous-lupus-erythematosus\" class=\"medical medical_review\">Overview of cutaneous lupus erythematosus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-pemphigus\" class=\"medical medical_review\">Pathogenesis, clinical manifestations, and diagnosis of pemphigus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=seborrheic-dermatitis-the-basics\" class=\"medical medical_basics\">Patient education: Seborrheic dermatitis (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=seborrheic-dermatitis-including-dandruff-and-cradle-cap-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Seborrheic dermatitis (including dandruff and cradle cap) (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pityriasis-rosea\" class=\"medical medical_review\">Pityriasis rosea</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rosacea-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">Rosacea: Pathogenesis, clinical features, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-seborrheic-dermatitis\" class=\"medical medical_society_guidelines\">Society guideline links: Seborrheic dermatitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tinea-versicolor-pityriasis-versicolor\" class=\"medical medical_review\">Tinea versicolor (Pityriasis versicolor)</a></li></ul></div></div>","javascript":null}